Facing the Challenge of Post COVID-19 Pulmonary fibrosis: What is so unique about it?

Authors

  • Medha Ghose Sir Salimullah Medical College, Bangladesh
  • Tasbirul Islam Clinical Associate Professor, Indiana University School Of Medicine, Medical director, Division of Pulmonary & Critical Care Medicine, IU Arnett Hospital, Lafayette, IN 47906, USA

DOI:

https://doi.org/10.3329/bccj.v8i2.50028

Keywords:

COVID-19, ARDS

Abstract

COVID-19 pandemic is the highlight of the 21st century that took drastic effects on humanity. Over 23 million confirm infected with the majority with mild infection. However, over 62,000 cases are in critical condition with varying degrees of ARDS. A potential complication of severe ARDS could be Post COVID-19 Pulmonary fibrosis. Possible use of biomarkers to detect progression to fibrosis, along with prompt treatment of acute lung injury caused by COVID-19 and administration anti-fibrotic therapies, could be the next best method to treat this permanent and devastating sequela of COVID-19.

Bangladesh Crit Care J September 2020; 8(2): 102-107

Downloads

Download data is not yet available.
Abstract
2
PDF
3

Downloads

Published

2020-11-01

How to Cite

Ghose, M., & Islam, T. (2020). Facing the Challenge of Post COVID-19 Pulmonary fibrosis: What is so unique about it?. Bangladesh Critical Care Journal, 8(2), 102–107. https://doi.org/10.3329/bccj.v8i2.50028

Issue

Vol. 8 No. 2 (2020)

Section

Review Articles

License

Upon acceptance for publication the copyright of the paper automatically transfers to the BCCJ and will not be published elsewhere either in part or whole without written permission of the copyright holder.

Except for personal use, no part of the materials published in this journal may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, photocopying, recording or otherwise without the prior written permission of the publisher.